stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Total debt
Trulieve Cannabis Corp.'s total debt at the end of fiscal 2025 was $291.7M, down 46.4% from $544.5M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $345.0M. Over the past ten years it has ranged from $291.7M (fiscal 2025) to $705.9M (fiscal 2022) — the current reading is the lowest in ten years. Trulieve Cannabis Corp. ranks 25th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $291.7M | (46.42%) |
| FY2024 | $544.5M | 0.69% |
| FY2023 | $540.7M | (23.39%) |
| FY2022 | $705.9M | 32.03% |
| FY2021 | $534.6M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $345.0M | (4.20%) |
| Mar 2026 | $360.2M | 23.46% |
| Dec 2025 | $291.7M | (45.88%) |
| Sep 2025 | $539.0M | (1.64%) |
| 15 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PRGO Perrigo Company plc compare | $3.3B |
| PBH Prestige Consumer Healthcare Inc. compare | $2.0B |
| ALVO Alvotech compare | $1.3B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $839.4M |
| TRLV Trulieve Cannabis Corp. | $345.0M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $94.5M |
| ANIP ANI Pharmaceuticals, Inc. compare | $23.4M |
| RGC Regencell Bioscience Holdings Limited compare | $463.7K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement